医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Dr. Reddy’s Announces the Launch of Esomeprazole Magnesium Delayed-Release Capsules USP, 20 mg in the U.S. Market

2018年07月20日 PM03:13
このエントリーをはてなブックマークに追加


 

HYDERABAD, India & PRINCETON, N.J.

Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the launch of Esomeprazole Magnesium Delayed-Release Capsules USP, 20 mg, an over-the-counter (OTC) therapeutic equivalent generic version of Nexium® 24HR Capsules in the United States market as approved by the U.S. Food and Drug Administration (USFDA).

Esomeprazole Magnesium Delayed-Release Capsules USP, 20 mg, is an OTC proton pump inhibitor used to treat frequent heartburn occurring two or more days a week in adults*.

“This launch continues to demonstrate our deep R&D and manufacturing capabilities to bring newer store-brand OTC medications to the market,” says Milan Kalawadia, Vice President and Head, US OTC and Speciality Rx businesses, Dr. Reddy’s Laboratories. “We look forward to collaborating with our customers to provide high-quality, affordable alternatives to consumers.”

The combined market of Nexium® 24HR Capsules and private label OTC Esomeprazole Magnesium products had U.S. sales of approximately $311 million for the most recent twelve months ending in May 2018 according to IRI.

Dr. Reddy’s Esomeprazole Magnesium Delayed-Release Capsules USP, 20 mg is available in 14 count bottles sold in cartons of 1, 2, or 3 bottles each. Each bottle contains a complete 14-day course of treatment. Use only as directed.

*May take 1 to 4 days for full effect. IRI Latest 52 wks. period ending May 2018
Nexium® is a registered trademark of AstraZeneca AB.

OTC-002-0618

About Dr. Reddy’s: Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses – Pharmaceutical Services & Active Ingredients, Global Generics and Proprietary Products – Dr. Reddy’s offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr. Reddy’s operates in markets across the globe. Our major markets include – USA, India, Russia & CIS countries, and Europe. For more information, log on to: www.drreddys.com.

Disclaimer: This press release may include statements of future expectations and other forward-looking statements that are based on the management’s current views and assumptions and involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the words “may”, “will”, “should”, “expects”, “plans”, “intends”, “anticipates”, “believes”, “estimates”, “predicts”, “potential”, or “continue” and similar expressions identify forward-looking statements. Actual results, performance or events may differ materially from those in such statements due to without limitation, (i) general economic conditions such as performance of financial markets, credit defaults , currency exchange rates , interest rates , persistency levels and frequency / severity of insured loss events (ii) mortality and morbidity levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganization , including related integration issues.

The company assumes no obligation to update any information contained herein.

View source version on businesswire.com: https://www.businesswire.com/news/home/20180719006015/en/

CONTACT

Dr. Reddy’s Laboratories Ltd.
INVESTOR RELATIONS
SAUNAK
SAVLA, +91-40-49002135
saunaks@drreddys.com
or
MEDIA
RELATIONS

CALVIN PRINTER, +91-40-49002121
calvinprinter@drreddys.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • Urban Drinking Water Challenge 2018 Announces Winners from USA, India and Bangladesh
  • CANbridge Life Sciences Receives Approval to Commence CAN017 Ib/III Trial in Esophageal Squamous Cell Cancer (ESCC) In China
  • AVEO Announces Acceptance of CANbridge Investigational New Drug Application for CAN017 (AV-203) Trial in Esophageal Squamous Cell Cancer (ESCC) in China
  • STAAR Surgical and Shinjuku LASIK Clinic in Japan Announce Strategic Cooperation Agreement
  • 新研究调查诊断性多通道睡眠检查之前采用Masimo SET®脉搏氧饱和度仪居家监测筛查唐氏综合征患儿罹患阻塞性睡眠呼吸暂停的风险